암성 통증 특강 안내
일시 : 3월 15일(화) 오후 6시
장소 : 지하2층 세미나실
연자 :Bart Morlion, MD, PhD
Professor Morlion trained as an anaesthesiologist, is director of the Leuven Centre for Algology
& Pain Management at the University Hospitals of Leuven and professor at the University of Leuven. He teaches pain management and pharmacology at the KU Leuven and several university colleges in Belgium. He is also appointed as Honorary Associate Professor at the University of Groningen in the Netherlands.
He is member of the utive board of the European Pain Federation EFIC as President Elect, to take office in 2017. From 2006 till end of 2012 he has been the President of the Belgian Pain Society ? the Belgian Chapter of the IASP and represented Belgium as councillor in the European Pain Federation EFIC from 2006-2013. He is program director of the Belgian Interuniversity Postgraduate Studies in Algology and is also an active member of several committees in international scientific societies (EFIC and IASP). He is section editor of the European Journal of Pain and regular peer reviewer for many journals.
His professional interests include all aspects of multimodal chronic pain management, cancer pain management, pharmacotherapy of pain, and quality management.
▣ Speaker : Prof. Morlion (anesthesiologist, director of the Leuven Centre for Pain Management at the University Hospitals of Leuven)
▣ Lecture subject :
1. Why Oxycodone?, Clinical properties that we can expected in cancer.?
2. Differentiation of Oxycodone, Oxycodone/Naloxone versus especially Fentanyl based on the pharmacological feature.
3. Are opioids receptor polymorphism important in clinical practice of Korea?
- Oxycodone is rarely impacted by genetic variations (A118G SNP of mu-opioids receptor) vs other Opioids (Fentanyl, Morphine..)
How? - Different potential and mechanism of tolerance, withdrawal, addiction among the opioids.
4. What kinds of (opioids) feature should be considered in clinical field ?